Dapagliflozin/Metformin Combo Nears EU Approval for DiabetesDapagliflozin/Metformin Combo Nears EU Approval for Diabetes
The first product combining metformin with an SGLT2 inhibitor, dapagliflozin, has been granted a positive opinion by the European Medicines Agency for use in type 2 diabetes. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | European Medicines Agency (EMA) | Fortamet | Forxiga | Metformin | SGLT2 Inhibitors